MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Wang, Chen ^a   Zheng, Xiangqian ^a   Shen, Chunyan ^b   Shi, Yurong ^c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Department of Medical Oncology   (China)

^c KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

baculoviral IAP repeat containing protein 5; Lim and SH3 domain protein 1; Migration; MiR 203; Proliferation; Triple negative breast cancer

Indexed keywords

BIRC5 PROTEIN; LASP1 PROTEIN; LUCIFERASE; MICRORNA; MICRORNA 203; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN CONTENT; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; CYTOSKELETAL PROTEINS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIM DOMAIN PROTEINS; MICRORNAS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84862276687     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-58     Document Type: Article

References (30)

1. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 69 90 10.3322/caac.20107 21296855
2. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N, Basyuk E, Bertrand E, Filipowicz W, Science 2005 309 1573 1576 10.1126/science.1115079 16081698
3. MicroRNA function: multiple mechanisms for a tiny RNA? Pillai RS, RNA 2005 11 1753 1761 10.1261/rna.2248605 16314451
4. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM, Proc Natl Acad Sci 2004 101 2999 3004 10.1073/pnas.0307323101 14973191
5. MicroRNA expression profiles classify human cancers. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR, Nature 2005 435 834 838 10.1038/nature03702 15944708
6. Principles and effects of microRNA-mediated post-transcriptional gene regulation. Engels BM, Hutvagner G, Oncogene 2006 25 6163 6169 10.1038/sj.onc.1209909 17028595
7. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Bartel DP, Chen CZ, Nat Rev Genet 2004 5 396 400 15143321
8. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. Bao B, Ali S, Kong D, Sarkar SH, Wang Z, Banerjee S, Aboukameel A, Padhye S, Philip PA, Sarkar FH, PLoS One 2011 6 17850 10.1371/journal.pone.0017850 21408027
9. MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development. Heyn H, Engelmann M, Schreek S, Ahrens P, Lehmann U, Kreipe H, Schlegelberger B, Beger C, Int J Cancer 2011 129 2797 2806 10.1002/ijc.25962 21618216
10. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Bueno MJ, Pérez De Castro I, Gámez De Cedrán M, Santos J, Calin GA, Cigudosa JC, Croce CM, Fernández-Piqueras J, Malumbres M, Cancer Cell 2008 13 496 506 10.1016/j.ccr.2008.04.018 18538733
11. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J, Carcinogenesis 2010 31 766 776 10.1093/carcin/bgp250 19843643
12. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC, JAMA 2008 299 425 436 10.1001/jama.299.4.425 18230780
13. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Boll K, Reiche K, Kasack K, Mörbt N, Kretzschmar AK, Tomm JM, Verhaegh G, Schalken J, von Bergen M, Horn F, Hackermüller J, Oncogene 2012 10.1038/onc.2012.55
14. MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin. Bian K, Fan J, Zhang X, Yang XW, Zhu HY, Wang L, Sun JY, Meng YL, Cui PC, Cheng SY, Zhang J, Zhao J, Yang AG, Zhang R, FEBS Lett 2012 586 804 809 10.1016/j.febslet.2012.01.050 22306317
15. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Hummel R, Hussey DJ, Haier J, Eur J Cancer 2010 46 298 311 10.1016/j.ejca.2009.10.027 19948396
16. Targeting microRNAs in cancer: rationale, strategies and challenges. Garzon R, Marcucci G, Croce CM, Nat Rev Drug Discov 2010 9 775 789 10.1038/nrd3179 20885409
17. MicroRNA-203 inhibits cell proliferation by repressing Np63 expression in human esophageal squamous cell carcinoma. Yuan Y, Zeng ZY, Liu XH, Gong DJ, Tao J, Cheng HZ, Huang SD, BMC Cancer 2011 11 57 10.1186/1471-2407-11-57 21299870
18. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Ambrosini G, Adida C, Altieri DC, Nat Med 1997 3 917 921 10.1038/nm0897-917 9256286
19. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Taniga-wa N, Clin Cancer Res 2000 6 127 134 10656440
20. IAPs: more than just inhibitors of apoptosis proteins. Dubrez-Daloz L, Dupoux A, Cartier J, Cell Cycle 2008 7 1036 1046 10.4161/cc.7.8.5783 18414036
21. The case for survivin as a regulator of microtubule dynamics and cell death decisions. Altieri DC, Curr Opin Cell Biol 2006 18 609 615 10.1016/j.ceb.2006.08.015 16934447
22. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Hinnis A, Luckett J, Walker R, Br J Cancer 2007 96 639 645 10.1038/sj.bjc.6603616 17285125
23. Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer. Petrarca CR, Brunetto AT, Duval V, Brondani A, Carvalho GP, Garicochea B, Clin Breast Cancer 2011 11 129 134 10.1016/j.clbc.2011.03.002 21569999
24. Relevance of c-erbB-2, PLU-1 and survivin mRNA expression to diagnostic assessment of breast cancer. Izawa A, Kobayashi D, Nasu S, Saito K, Moriai R, Asanuma K, Nakamura M, Yagihashi A, Watanabe N, Anticancer Res 2002 22 2965 2969 12530026
25. Prognostic importance of survivin in breast cancer. Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Linehan R, Clynes M, Br J Cancer 2003 88 1077 1083 10.1038/sj.bjc.6600776 12671708
26. Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Ai Z, Yin L, Zhou X, Zhu Y, Zhu D, Yu Y, Feng Y, Cancer 2006 107 746 756 10.1002/cncr.22044 16826583
27. The LIM and SH3 domain protein family: structural proteins or signal transducers or both? Grunewald TG, Butt E, Mol Cancer 2008 7 31 10.1186/1476-4598-7-31 18419822
28. Silencing of LASP-1 influences zyxin localization, inhibits proliferation and reduces migration in breast cancer cells. Grunewald TG, Kammerer U, Schulze E, Schindler D, Honig A, Zimmer M, Butt E, Exp Cell Res 2006 312 974 982 10.1016/j.yexcr.2005.12.016 16430883
29. Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localization. Grunewald TG, Kammerer U, Winkler C, Schindler D, Sickmann A, Honig A, Butt E, Br J Cancer 2007 96 296 305 10.1038/sj.bjc.6603545 17211471
30. Role of LIM and SH3 Protein 1 (LASP1) in the metastastic dissemination of medulloblastoma. Traenka C, Remke M, Korshunov A, Bender S, Hielscher T, Northcott PA, Witt H, Ryzhova M, Felsberg J, Benner A, Riester S, Scheurlen W, Grunewald TG, von Deimling A, Kulozik AE, Reifenberger G, Taylor MD, Lichter P, Butt E, Pfister SM, Cancer Res 2010 70 8003 8014 10.1158/0008-5472.CAN-10-0592 20924110